Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.62 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.62 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7210216 | 0.77 | PTGS2 (0.48) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL7215179 | 0.73 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL7210423 | 0.71 | ADORA1 (0.51) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL7215030 | 0.71 | BRAF (0.51) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL7222483 | 0.70 | ADORA1 (0.75) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL7210472 | 0.70 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL7210550 | 0.70 | ADORA1 (0.75) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL7210591 | 0.70 | PTGS2 (0.49) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL7211811 | 0.70 | PTGS2 (0.68) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL7215273 | 0.69 | PTGS2 (0.53) | MAPK14MAPK13MAPK12MAPK11MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610698-B2 | Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases | AMGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1314731-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1314732-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | AMGEN INC. | 2003-04-10 | — | — | US | disclosed |
| US-6410729-B1 | ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS | AMGEN INC. | 2002-06-25 | — | — | US | disclosed |
| EP-0948497-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024782-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | DPYD, IL6, IL1B | MAPK14 2062/4885MAPK13 2250/4885MAPK12 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.